Harnessing Antitumor CD4 + T Cells for Cancer Immunotherapy.

Over the past decades, CD4 + T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4 + T cells during antitumor immunity. CD4 + T cells can either suppress or promote the antitumor cytotoxic CD8 + T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4 + T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4 + T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4 + T cells to control tumor progression and prevent recurrence in patients.